Please assess the completion status of the following clinical trial:

Trial Title: A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent.~* Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening.~* Glycosylated haemoglobin (HbA1c) of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory.~* Treated with once daily or twice daily basal insulin analogue (insulin degludec, insulin detemir, insulin glargine U100 or U300, total daily dose of 10-50 U, both inclusive) greater than or equal to 90 days prior to the day of screening.~* Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):~  1. Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical records).~ 2. Free or fixed combination therapy: Metformin as outlined above with or without dipeptidyl peptidase 4 inhibitors (DPP4i) with or without sodium-glucose cotransporter 2 inhibitors (SGLT2i) is allowed: 1) DPP4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose); 2) SGLT2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose.~* Body mass index (BMI) less than or equal to 40.0 kg/m\^2.~Exclusion criteria:~* Known or suspected hypersensitivity to trial product(s) or related products.~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method.~* Participation in any clinical trial of an approved or non-approved investigational medicinal product within 90 days before screening.~* Any disorder, except for conditions associated with type 2 diabetes mellitus, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.~* Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of screening and between screening and randomisation.~* Known hypoglycaemic unawareness as indicated by the Investigator according to Clarke's questionnaire question 8.~* Recurrent severe hypoglycaemic episodes within the last year as judged by the Investigator.~* Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening and between screening and randomisation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin 287 (with 100% loading dose) (Type: EXPERIMENTAL): Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
- Insulin 287 (without loading dose) (Type: EXPERIMENTAL): Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
- Insulin glargine U100 (Type: ACTIVE_COMPARATOR): Participants will receive insulin glargine U100 once daily (OD).

Based on this trial design, predict the completion outcome and termination type (if applicable).